Medlab Clinical Limited (MDC) 2021年年度报告「ASX」.pdf

《Medlab Clinical Limited (MDC) 2021年年度报告「ASX」.pdf》由会员分享，可在线阅读，更多相关《Medlab Clinical Limited (MDC) 2021年年度报告「ASX」.pdf（68页珍藏版）》请在三个皮匠报告上搜索。

1、Copyright Medlab Clinical Ltd 2021MEDLAB CLINICAL LIMITED(ABN 51 169 149 071)ANNUAL REPORTFOR THE YEAR ENDED 30 JUNE 2021ASX:MDCCeased all opioid medications after 3 months NanaBis with pain reduced from 15/10 to 3/1081 yo Female(Chronic pain,osteoarthritis with depression and anxiety)“This Oil Work

2、s”53 yo Female(severe chronic pain)“This is the first time with no pain in 20 years.I am able to function and do day to day activities”Pain score dropped from 10/10 to mostly 3/10 with some days 0/10.and now able to walk his dog over 1.5km which was previously unheard of.54 yo Male(Neuropathic pain)

3、Able to completely withdraw from all opioidsAfter 1 week on NanaBis pain reduced from 9/10 to 4/10 and other painmedications reduced or ceased.Additionally,nausea has reduced.75 yo Female(Pain associated with cancer)“After 2 days I can feel the pain relief”“I think the biggest innovations of the 21s

4、t century will be at the intersection of biology and technology.A new era is beginning”-Steve JobsCONTENTSChairmans Letter4CEO Report5Directors Report12Auditors Independence Declaration24Financial Statements25Directors Declaration59Independent Auditors Report60Shareholder Information63Corporate Dire

5、ctory64CHAIRMANS LETTERDear Shareholders,It is my pleasure to present Medlab Clinicals 2021 Annual Report.The past year has been a busy one for Medlab Clinical.The work required to develop our principal assetshas been intense,interesting,and demanding.This has been made more difficult by the overlay

6、 of COVIDpandemic restrictions.Our strategy is to expand our market opportunity by gaining US regulatory approval for our clinicallyvalidated,medical cannabis-based product(NanaBis).Furthermore,the superior performance we can achieve via ourdrug delivery platform,NanoCellewill be a key differentiato